Daniel Clair (Columbia, SC, USA), presented positive six-month data from the full patient cohort of the PROMISE I early feasibility study of the LimFlow percutaneous deep vein arterialisation system (LimFlow) as a late-breaking trial at VIVA 2019 (Vascular InterVentional Advances; 4–7 November, Las Vegas, USA).
He tells Vascular News the PROMISE I trial dataset reveals that the dedicated LimFlow System for percutaneous deep vein arterialisation may improve wound healing and reduce amputation rates in end-stage critical limb ischaemia patients, who are facing a major amputation, so that patients can retain their limbs and functional status. Uniquely, says Clair, these patients have never been evaluated in any interventional trial in the past.
One of the data highlights from the study was a 74% amputation-free survival rate in this group of patients who could not be offered other revascularisation options, as determined by an oversight committee, leading Clair to note that the use of this system could stop their “march to amputation”.
This video was sponsored by LimFLow.
Add comment